Promising therapeutic approaches such as blockade of IL-6 trans signaling via sGP130Fc may have the potential for combinatory therapies with similar pharmacological perspectives against the leptin receptor to ultimately reduce deaths from HCC. The gene discussed is LEPR; the disease is hepatocellular carcinoma.